Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Open Vs Robotic-Assisted Radical Cystectomy: A Randomized Trial

This study is ongoing, but not recruiting participants.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Dipen J Parekh, MD, University of Miami Identifier:
First received: June 30, 2010
Last updated: November 20, 2016
Last verified: November 2016
This is a multi-institutional, randomized trial evaluating oncologic, perioperative, and functional outcomes following two standard care procedures for radical cystectomy. The participants will have one of the standard care procedures as part of their care. The two procedures that will be followed are open radical cystectomy and robotic assisted radical cystectomy (RARC). Open cystectomy is considered to be the more traditional approach. While newer, RARC is considered to be equivalent to open surgery when it is performed by a trained robotics surgeon. The reported complication rates of RARC appear comparable to open surgery. This means there is no significant difference in the risk between the two standard procedures. However, despite these potential advantages, true comparison between the open and robotic technique with regards to long term cancer related and functional outcomes has not been accomplished because previous studies did not compare patients of equal health status. The researchers hope to learn whether or not patients undergoing RARC recover more quickly than or at the same rate as patients undergoing an open radical cystectomy while having non inferior cancer related outcomes. This study is funded by the National Institutes of Health (NIH).

Condition Intervention
Bladder Cancer Requiring Cystectomy
Other: Quality of Life Questionnaires
Other: Get up and Go test
Other: Hand Grip test

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Open Vs Robotic-Assisted Radical Cystectomy: A Randomized Trial

Resource links provided by NLM:

Further study details as provided by University of Miami:

Primary Outcome Measures:
  • Determine if RARC provides a non inferior oncologic control to open radical cystectomy, as measure by two-year progression free survival. [ Time Frame: 36 months ]

Enrollment: 350
Study Start Date: March 2009
Estimated Study Completion Date: November 2017
Estimated Primary Completion Date: November 2017 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Open cystectomy
Standard of care treatment
Other: Quality of Life Questionnaires
Quality of Life Questionnaires
Other: Get up and Go test
Timed Get up and Go test
Other: Hand Grip test
Hand grip strength test
Robotic assisted radical cystectomy
Standard of care treatment
Other: Quality of Life Questionnaires
Quality of Life Questionnaires
Other: Get up and Go test
Timed Get up and Go test
Other: Hand Grip test
Hand grip strength test


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Bladder cancer patients who are a candidate for radical cystectomy.

Inclusion Criteria:

  1. Patient must have biopsy proven bladder cancer. Official pathology report reviewed at the participating institution is required.
  2. Bladder cancer must be clinical stage T1-T4, N0-1, M0. (AJCC 7th edition) or refractory cis (carcinoma in situ).

Exclusion Criteria:

  1. Inability to give informed consent.
  2. Prior major abdominal and pelvic open surgical procedures that would preclude a safe robotic approach, as determined by the treating surgeon.
  3. At the discretion of the treating surgeon, any pre-existing condition such as severe chronic obstructive pulmonary disease that precludes a safe initiation or maintenance of pneumoperitoneum over a prolonged period of time and during surgery.
  4. Age <18 or >99 years.
  5. Pregnancy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01157676

United States, Arizona
Mayo Clinic Arizona
Phoenix, Arizona, United States, 85054
United States, California
University of California, Irvine Medical Center (UC Irvine)
Orange, California, United States, 92868
Stanford University
Stanford, California, United States, 94305
United States, Florida
University of Miami
Miami, Florida, United States, 33136
United States, Illinois
University of Chicago Medical Center
Chicago, Illinois, United States, 60637
Loyola University Medical Center
Maywood, Illinois, United States, 60153
United States, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
United States, Michigan
University of Michigan Health System
Ann Arbor, Michigan, United States, 48109
United States, Minnesota
University of Minnesota
Minneapolis, Minnesota, United States, 55455
Mayo Clinic
Rochester, Minnesota, United States, 55905
United States, North Carolina
University of North Carolina
Chapel Hill, North Carolina, United States, 27599
United States, Ohio
Ohio State University Medical Center
Columbus, Ohio, United States, 43210
United States, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232
United States, Texas
The University of Texas Health Science Center at San Antonio, Medical Arts & Research Center
San Antonio, Texas, United States, 78229
United States, Virginia
University of Virginia Health Science Center, Department of Urology
Charlottesville, Virginia, United States, 22908
United States, Washington
Cancer Research and Biostatistics (Data Management and Statistical Office)
Seattle, Washington, United States, 98101
Sponsors and Collaborators
University of Miami
National Cancer Institute (NCI)
Principal Investigator: Dipen J Parekh, MD University of Miami
  More Information

Responsible Party: Dipen J Parekh, MD, Chairman of Urology, University of Miami Identifier: NCT01157676     History of Changes
Other Study ID Numbers: 20120408
R01CA155388 ( US NIH Grant/Contract Award Number )
36911 ( Other Identifier: Investigator-Assigned ID )
Study First Received: June 30, 2010
Last Updated: November 20, 2016

Keywords provided by University of Miami:
open cystectomy
robotic assisted radical cystectomy
bladder cancer

Additional relevant MeSH terms:
Urinary Bladder Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Urinary Bladder Diseases
Urologic Diseases processed this record on April 27, 2017